Back to Authors

Neste, Éric Van Den

A5109532470 | I1315288073

Mayo Clinic

Cliniques Universitaires Saint-Luc

Citations 3

Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7516-7516

10.1200/jco.2016.34.15_suppl.7516

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Blood | April 17, 2018 | Volume: 132 | Issue: 1 | Pages: 49-58

10.1182/blood-2017-11-816405 | PMID 29666118

Key Points In FL, no prognostic index has been built based solely on a large cohort of patients treated with initial immunochemotherapy. The PRIMA-PI is a simplified index based on β2m and bone marrow involvement for patients treated with immunochemotherapy.
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Blood | August 3, 2017 | Volume: 130 | Issue: 16 | Pages: 1800-1808

10.1182/blood-2017-03-769620 | PMID 28774879

Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.